Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial

Thumbnail Image
s13063-019-3955-6.pdf(836.7 KB)
Published Version
13063_2019_3955_MOESM1_ESM.doc(122 KB)
Additional File 1
13063_2019_3955_MOESM2_ESM.docx(75.65 KB)
Additional File 2
13063_2019_3955_MOESM3_ESM.docx(61.23 KB)
Additional File 3
13063_2019_3955_MOESM4_ESM.docx(18.15 KB)
Additional File 4
Hansen, Mathias Luhr
Pellicer, Adelina
Gluud, Christian
Dempsey, Eugene M.
Mintzer, Jonathan
Hyttel-Sorensen, Simon
Heuchan, Anne Marie
Hagmann, Cornelia
Ergenekon, Ebru
Dimitriou, Gabriel
Journal Title
Journal ISSN
Volume Title
Springer Nature
Research Projects
Organizational Units
Journal Issue
Background: Cerebral oxygenation monitoring may reduce the risk of death and neurologic complications in extremely preterm infants, but no such effects have yet been demonstrated in preterm infants in sufficiently powered randomised clinical trials. The objective of the SafeBoosC III trial is to investigate the benefits and harms of treatment based on near-infrared spectroscopy (NIRS) monitoring compared with treatment as usual for extremely preterm infants.Methods/design: SafeBoosC III is an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial. Inclusion criteria will be infants born below 28 weeks postmenstrual age and parental informed consent (unless the site is using 'opt-out' or deferred consent). Exclusion criteria will be no parental informed consent (or if 'opt-out' is used, lack of a record that clinical staff have explained the trial and the 'opt-out' consent process to parents and/or a record of the parents' decision to opt-out in the infant's clinical file); decision not to provide full life support; and no possibility to initiate cerebral NIRS oximetry within 6 h after birth. Participants will be randomised 1:1 into either the experimental or control group. Participants in the experimental group will be monitored during the first 72 h of life with a cerebral NIRS oximeter. Cerebral hypoxia will be treated according to an evidence-based treatment guideline. Participants in the control group will not undergo cerebral oxygenation monitoring and will receive treatment as usual. Each participant will be followed up at 36 weeks postmenstrual age. The primary outcome will be a composite of either death or severe brain injury detected on any of the serial cranial ultrasound scans that are routinely performed in these infants up to 36 weeks postmenstrual age. Severe brain injury will be assessed by a person blinded to group allocation. To detect a 22% relative risk difference between the experimental and control group, we intend to randomise a cohort of 1600 infants.Discussion: Treatment guided by cerebral NIRS oximetry has the potential to decrease the risk of death or survival with severe brain injury in preterm infants. There is an urgent need to assess the clinical effects of NIRS monitoring among preterm neonates.
Observer bias , Outcomes , Injury , Interventions , Standard
Hansen, M. L., Pellicer, A., Gluud, C., Dempsey, E. M., Mintzer, J., Hyttel-Sorensen, S., Heuchan, A-M., Hagmann, C., Ergenekon, E., Dimitriou, G., Pichler, G., Naulaers, G., Cheng, G., Guimaraes, H., Tkaczyk, J., Kreutzer, K. B., Fumagalli, M., Claris, O., Lemmers, P., Fredly, S., Szczapa, T., Austin, T., Jakobsen, J. C. and Greisen, G. (2019) 'Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial', Trials, 20, 811 (11pp). doi: 10.1186/s13063-019-3955-6
Link to publisher’s version